First-Line Zongertinib in Advanced HER2-Mutant NSCLC: A New Targeted Standard Begins to Take Shape

oncodaily - For years, HER2-mutant non-small-cell lung cancer sat in an uncomfortable place in thoracic oncology. It was clearly an oncogene-driven disease, but unlike EGFR-mutant or ALK-rearranged NSCLC, it did not have […]

AI Summary: Clinical trial data show zongertinib delivers strong antitumor activity as a first‑line treatment for patients with advanced HER2‑mutant non‑small cell lung cancer, positioning the drug as a potential new targeted standard. Robust response rates in previously untreated patients are prompting clinicians to rethink initial treatment choices while attention turns to long‑term safety and access.

Eating more fruits and vegetables tied to unexpected lung cancer risk

sciencedaily - A surprising new study suggests that eating a very healthy diet—packed with fruits, vegetables, and whole grains—might be linked to a higher risk of lung cancer in younger non-smokers. Researchers found that patients under 50 diagnosed with lung cancer of…

AI Summary: A new analysis links higher fruit-and-vegetable consumption to an unexpected rise in lung cancer risk among younger non‑smokers, with investigators pointing to pesticide residues on produce as a likely culprit. Researchers urge careful interpretation—don’t ditch your salad—while calling for stricter residue limits, better monitoring, and further study to untangle diet, toxins, and cancer risk.

Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors

Frank Vinluan / medcitynews - Eli Lilly is paying up to $300 million for CrossBridge Bio, a startup developing antibody drug conjugates that deliver two drug payloads to cancers. Beyond potentially better efficacy, CrossBio’s dual approach could also fight drug resistance. The post El…

AI Summary: Eli Lilly agreed to acquire CrossBridge Bio for up to $300 million, adding small‑molecule oncology assets to its pipeline. The deal accelerates Lilly’s tumor‑targeting strategy, reflects Big Pharma’s preference for buying nimble biotech innovation, and highlights ongoing consolidation trends that determine where promising oncology programs ultimately end up.

ESMO 2026 Guideline: Redefining the Management of Metastatic Colorectal Cancer

oncodaily - Metastatic colorectal cancer (mCRC) represents a complex and biologically diverse disease in which treatment decisions increasingly depend on molecular characteristics, disease burden, and patient-specific factors. While therapeutic options have expanded …

AI Summary: The European Society for Medical Oncology released updated clinical practice guidelines for metastatic colorectal cancer, redefining diagnostic pathways, systemic therapy sequencing, and follow‑up standards. The guidance incorporates recent targeted and immunotherapy evidence to recommend practical treatment algorithms, prompting oncology centers to update protocols and payers to reassess coverage as clinicians translate recommendations into routine care.